FEU is March 2013 MedTech Board Exam Top Performing School


ADVERTISEMENT


The Professional Regulation Commission (PRC) announces today, 25 March 2013 that 641 out of 915 (70.05%) passed the Medical Technologist (MedTech) Licensure Examination given by the Board of Medical Technology in the cities of Manila, Baguio and Cebu this March 2013. As per Commission Resolution No. 2010-547 series of 2010, FEU- Manila is the only top performing school with63 out of 69 grads passed the board or 91.30 in percentage.

[ Click here for the list of passers and topnotchers ]

The members of the Board of Medical Technology who gave the licensure examination are Dr. Marietta C. Baccay, Chairman; Ms. Marilyn R. Atienza and Ms. Marian M. Tantingco, Members.
The results were released in three (3) working days from the last day of examination.

Registration for the issuance of Professional Identification Card (ID) and Certificate of Registration will be on April 3 and 4, 2013. Those who will register are required to bring the following: duly accomplished Oath Form or Panunumpa ng Propesyonal, current Community Tax Certificate (cedula), 2 pieces passport size picture (colored with white background and complete name tag), 1 piece 1” x 1” picture (colored with white background and complete name tag), 2 sets of metered documentary stamps and 1 short brown envelope with name and profession and to pay the Initial Registration Fee of P600 and Annual Registration Fee of P450 for 2013-2016. Successful examinees should personally register and sign in the Roster of Registered Professionals.

Those who failed to pass the board examination for Medical Technology but had obtained a general rating of at least 70% can register as Medical Laboratory Technician, PRC said.

The date and venue for the oathtaking ceremony of the new successful examinees in the said examination WILL BE ANNOUNCED LATER.

Here is the full text and list of performance of schools for March 2013 MedTech Board Exam:


 

Don't miss our regular updates and awesome stories, Like us on Facebook, follow us on Twitter or subscribe via E-mail.


ADVERTISEMENT